OSTF1: A Promising Cancer Treatment and Biomarker (G26578)

Target Name: OSTF1

NCBI ID: G26578

OSTF1

OSTF1: A Promising Cancer Treatment and Biomarker

OSTF1 (Ba235O14.1) is a rare earth metal ion with a high affinity for actinium, which is a radioactive isotope with a half-life of about 12 years. OSTF1 has been identified as a potential drug target or biomarker for various diseases, including cancer, and has shown promise in pre-clinical studies for treating multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.

The OSTF1 ion has been shown to have a unique quantum mechanical property called鈥渟uper-radiant鈥? which gives it a very short lifetime of about 1.4 seconds. This property makes it a useful tool for studying the structure and function of actinium ions, which are often used in cancer treatments.

Additionally, OSTF1 has a high affinity for actinium, which means it can easily bind to and incorporate into actinium ions. This high affinity makes OSTF1 an attractive candidate for actinium-based cancer treatments.

In pre-clinical studies, OSTF1 has been shown to be effective in treating multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Studies have shown that OSTF1 can effectively kill multiple myeloma cells, both in aqueous solution and in a cell-free format.

The reason why OSTF1 is effective in treating multiple myeloma is that it is able to enter into the cells and interact with the actinium ions, which are often used in cancer treatments. This interaction allows OSTF1 to act as a delivery agent for the actinium ions, which can then accumulate in the cells and cause damage to the DNA and RNA in the cells.

Another potential mechanism of OSTF1's effectiveness in treating multiple myeloma is its ability to stimulate the production of apoptotic cells, which can help to eliminate cancer cells. This is done by OSTF1 induceing the cells to enter into apoptosis via increased production of activating transcription factor-3 (ATF-3), which is a protein that promotes cell death.

In addition to its potential as a cancer treatment, OSTF1 has also been shown to have potential as a biomarker for multiple myeloma. Studies have shown that OSTF1 levels are significantly higher in multiple myeloma patients than in healthy individuals, which could be used as a diagnostic marker for this disease.

Furthermore, OSTF1 has been shown to have a unique quantum mechanical property called鈥渟uper-radiant鈥? which gives it a very short lifetime of about 1.4 seconds. This property makes it a useful tool for studying the structure and function of actinium ions, which are often used in cancer treatments.

In conclusion, OSTF1 (Ba235O14.1) is a rare earth metal ion with a high affinity for actinium, which is a radioactive isotope with a half-life of about 12 years. OSTF1 has been identified as a potential drug target or biomarker for various diseases, including cancer, and has shown promise in pre-clinical studies for treating multiple myeloma. Its ability to enter into cells, interact with actinium ions, and stimulate the production of apoptotic cells make it an attractive candidate for cancer treatments. Furthermore, its unique quantum mechanical property called鈥渟uper-radiant鈥? makes it a useful tool for studying the structure and function of actinium ions.

Protein Name: Osteoclast Stimulating Factor 1

Functions: Induces bone resorption, acting probably through a signaling cascade which results in the secretion of factor(s) enhancing osteoclast formation and activity

The "OSTF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OSTF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets